[Palivizumab in viral respiratory infections].
Grell
Lili
L
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000145:classification / Q000627:therapeutic use*; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy / Q000821:virology; D009439:Neuraminidase / Q000037:antagonists & inhibitors*; D000069455:Palivizumab; D010818:Practice Patterns, Physicians'; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000821:virology*; D012794:Sialic Acids / Q000627:therapeutic use*; D016896:Treatment Outcome; D014777:Virus Diseases / Q000188:drug therapy*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D012794:Sialic Acids; D000069455:Palivizumab; D009439:Neuraminidase
Pediatr Infect Dis J. 2004 Apr;23(4):342-5
15071290
Pediatr Infect Dis J. 2004 Aug;23(8):707-12
15295219
Pediatr Infect Dis J. 1998 Feb;17(2):110-5
9493805
Pediatr Infect Dis J. 1998 Sep;17(9):787-91
9779762